Short-term Efficacy of Intravitreal Ranibizumab for Myopic Choroidal Neovascularization
Journal of the Korean Ophthalmological Society
;
: 1027-1034, 2009.
Article
in Korean
| WPRIM
| ID: wpr-94265
ABSTRACT
PURPOSE:
To evaluate the effects of intravitreal ranibizumab in myopic choroidal neovascularization (CNV).METHODS:
Patients who underwent intravitreal ranibizumab injection for myopic CNV, and were followed up more than 6 months, and their records were retrospectively investigated. The best corrected visual acuity, central macular thickness, and leak in fluorescein angiography were compared at baseline, and at 1, 3, and 6 months after injection.RESULTS:
Twenty-one eyes of 18 patients were evaluated. The mean best corrected visual acuity (logMAR) was 1.23+/-0.65, 0.96+/- 0.40, 0.95+/-0.67, and 0.83+/-0.58 at baseline, 1, 3, and 6 months, respectively (p<0.001, p=0.006, p=0.001). The mean central macular thickness was 233.42+/-65.55 microm, 204.14+/-65.29 micrometer, and 157.76+/-71.45 microm at baseline, 3, and 6 months, respectively (p<0.001). In fluorescein angiography at 6 months after injection, regression was observed in 12 eyes, and fibrosis in 9 eyes.CONCLUSIONS:
Intravitreal ranibizumab injection for myopic CNV in Korean patients appeared to be effective, resulting in regression of lesion and improvement of visual acuity.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Fibrosis
/
Fluorescein Angiography
/
Visual Acuity
/
Retrospective Studies
/
Choroid
/
Choroidal Neovascularization
/
Eye
/
Antibodies, Monoclonal, Humanized
/
Ranibizumab
Type of study:
Observational study
Limits:
Humans
Language:
Korean
Journal:
Journal of the Korean Ophthalmological Society
Year:
2009
Type:
Article
Similar
MEDLINE
...
LILACS
LIS